475 related articles for article (PubMed ID: 26634305)
41. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
Sydora MJ; Sydora BC; Fedorak RN
J Crohns Colitis; 2012 Mar; 6(2):207-14. PubMed ID: 22325175
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of the Quantum Blue® rapid test for faecal calprotectin.
Wassell J; Wallage M; Brewer E
Ann Clin Biochem; 2012 Jan; 49(Pt 1):55-8. PubMed ID: 21930735
[TBL] [Abstract][Full Text] [Related]
43. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease.
Naismith GD; Smith LA; Barry SJ; Munro JI; Laird S; Rankin K; Morris AJ; Winter JW; Gaya DR
Aliment Pharmacol Ther; 2013 Mar; 37(6):613-21. PubMed ID: 23347334
[TBL] [Abstract][Full Text] [Related]
44. [Fecal Calprotectin in Inflammatory Bowel Disease].
Lee J
Korean J Gastroenterol; 2016 May; 67(5):233-7. PubMed ID: 27206433
[TBL] [Abstract][Full Text] [Related]
45. [Faecal calprotectin in inflammatory bowel disease].
Sipponen T; Kolho KL
Duodecim; 2011; 127(24):2631-7. PubMed ID: 22320105
[TBL] [Abstract][Full Text] [Related]
46. Analytical and diagnostic performance of two automated fecal calprotectin immunoassays for detection of inflammatory bowel disease.
De Sloovere MMW; De Smet D; Baert FJ; Debrabandere J; Vanpoucke HJM
Clin Chem Lab Med; 2017 Aug; 55(9):1435-1446. PubMed ID: 28076305
[TBL] [Abstract][Full Text] [Related]
47. Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50 years.
Kennedy NA; Clark A; Walkden A; Chang JC; Fascí-Spurio F; Muscat M; Gordon BW; Kingstone K; Satsangi J; Arnott ID; Lees CW
J Crohns Colitis; 2015 Jan; 9(1):41-9. PubMed ID: 25135754
[TBL] [Abstract][Full Text] [Related]
48. The semi-quantitative calprotectin rapid test--is it useful in inflammatory bowel disease?
Dranga M; Dumitrescu G; Badea M; Blaj A; Mihai C; Prelipcean CC
Rev Med Chir Soc Med Nat Iasi; 2012; 116(3):761-5. PubMed ID: 23272524
[TBL] [Abstract][Full Text] [Related]
49. Fecal calprotectin levels in children is more tightly associated with histological than with macroscopic endoscopy findings.
Hradsky O; Ohem J; Mitrova K; Durilova M; Kotalova R; Nevoral J; Kolho KL; Bronsky J
Clin Lab; 2014; 60(12):1993-2000. PubMed ID: 25651733
[TBL] [Abstract][Full Text] [Related]
50. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
[TBL] [Abstract][Full Text] [Related]
51. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis.
Klingberg E; Strid H; Ståhl A; Deminger A; Carlsten H; Öhman L; Forsblad-d'Elia H
Arthritis Res Ther; 2017 Feb; 19(1):21. PubMed ID: 28148281
[TBL] [Abstract][Full Text] [Related]
52. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease.
Bunn SK; Bisset WM; Main MJ; Golden BE
J Pediatr Gastroenterol Nutr; 2001 Feb; 32(2):171-7. PubMed ID: 11321388
[TBL] [Abstract][Full Text] [Related]
53. Faecal calprotectin in the diagnosis of inflammatory bowel disease.
Burri E; Beglinger C
Biochem Med (Zagreb); 2011; 21(3):245-53. PubMed ID: 22420238
[TBL] [Abstract][Full Text] [Related]
54. Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study.
Voiosu T; Benguş A; Dinu R; Voiosu AM; Bălănescu P; Băicuş C; Diculescu M; Voiosu R; Mateescu B
J Gastrointestin Liver Dis; 2014 Sep; 23(3):273-8. PubMed ID: 25267955
[TBL] [Abstract][Full Text] [Related]
55. [Faecal calprotectin in inflammatory bowel diseases: review].
Kallel L; Fekih M; Boubaker J; Filali A
Tunis Med; 2011 May; 89(5):425-9. PubMed ID: 21557177
[TBL] [Abstract][Full Text] [Related]
56. The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease.
Kwapisz L; Gregor J; Chande N; Yan B; Ponich T; Mosli M
Scand J Gastroenterol; 2017 Aug; 52(8):846-850. PubMed ID: 28423962
[TBL] [Abstract][Full Text] [Related]
57. Rectal nitric oxide and fecal calprotectin in inflammatory bowel disease.
Reinders CA; Jonkers D; Janson EA; Stockbrügger RW; Stobberingh EE; Hellström PM; Lundberg JO
Scand J Gastroenterol; 2007 Oct; 42(10):1151-7. PubMed ID: 17852876
[TBL] [Abstract][Full Text] [Related]
58. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease.
Sipponen T; Kolho KL
Scand J Gastroenterol; 2010 Aug; 45(7-8):872-7. PubMed ID: 20377469
[TBL] [Abstract][Full Text] [Related]
59. Assessing the Correlation of Fecal Calprotectin and the Clinical Disease Activity Index in Patients With Ulcerative Colitis.
Amiriani T; Besharat S; Dadjou M; Roshandel G; Mirkarimi H; Salamat F; Joshaghani H
Gastroenterol Nurs; 2018; 41(3):201-205. PubMed ID: 29847394
[TBL] [Abstract][Full Text] [Related]
60. High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling?
Calafat M; Cabré E; Mañosa M; Lobatón T; Marín L; Domènech E
Inflamm Bowel Dis; 2015 May; 21(5):1072-6. PubMed ID: 25793326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
